Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cullinan Oncology & MABD Enter Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Cullinan Oncology & MABD Enter Collaboration

To develop novel antibody therapeutics based on MABD's unique discovery platform.

By: Betsy Louda

, Contract Pharma

Cullinan Oncology and MAB Discovery GmbH (MABD), announced the initiation of a collaboration to develop novel antibody therapeutics based on MABD’s unique discovery platform.

 

“We are excited to enter into this collaboration as the MABD development engine provides us with access to highly differentiated monoclonal antibodies” said Patrick Baeuerle, Cullinan’s chief scientific officer, Biologics. “Our first program is a novel agonistic antibody that has the potential to be a pillar of future immuno-oncology and standard treatments. We look forward to working with Stephan Fischer and the MABD team to execute the development plan and progress the asset into the clinic.”

 

Under the terms of the agreement, MABD has the potential to receive cash payments upon the achievement of various milestones in addition to an upfront equity interest in Cullinan Wittelsbach, a subsidiary of Cullinan Oncology LLC formed to fund and shepherd the development of the asset.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics